COLCHESTER, Conn., May 13, 2005 (PRIMEZONE) -- Scott + Scott, LLC, which filed on behalf of client shareholder a securities class action against GlaxoSmithKline plc (NYSE:GSK) earlier this week in the United States District Court for the Eastern District of Pennsylvania, states that it is prepared to litigate the case in this GSK industry center. The complaint charges GlaxoSmithKline and certain individual officers and directors with violations of the federal securities laws (Securities Exchange Act of 1934). GSK, with its subsidiaries, is a global healthcare conglomerate engaged in all phases of the pharmaceutical and consumer health-related products industry. GlaxoSmithKline's Philadelphia Headquarters are located at One Franklin Plaza, 16th and Race Streets, Philadelphia. In an agreement dated July 27, 2004 attached as an exhibit to a government filing, it states that, "28 Governing Law This Agreement shall be deemed a contract made under, and for all purposes shall be construed in accordance with, the laws of the Commonwealth of Pennsylvania. Each of the parties submits to the exclusive jurisdiction of the Commonwealth of Pennsylvania's courts as regards any claim or matter under this Agreement."

You can reach attorney Neil Rothstein at nrothstein@scott-scott.com at 800/332-2259 or 619/233-4565. If need be, you can also reach him at 619/251-0887. Attorney Amy K. Saba can be contacted at those numbers, as well, or at asaba@scott-scott.com . Scott + Scott has offices in Connecticut, Ohio and California. The firm (http://www.scott-scott.com) specializes in complex litigation including securities fraud and represents foundations, individuals, corporations and pension funds worldwide. The firm works on a contingency fee basis and therefore any costs or fees are awarded by the Court upon a successful result (there are no costs or fees to the shareholders.

ALLEGATIONS:

During the Class Period, it is alleged that the prices of GlaxoSmithKline's stock and ADRs were artificially inflated by defendants concealing deficiencies with the Company's selective serotonin reuptake inhibitor ("SSRI") drug, Paxil, in treating adolescent depression. On August 5, 2004, The Wall Street Journal published an article that reported that a new analysis by the FDA had confirmed the link between SSRIs (including Paxil) and suicidal tendencies in young people. The prices of GlaxoSmithKline's stock and ADRs, which were inflated during the Class Period, declined as the falsity of defendants' statements came to light.

Plaintiff seeks to recover damages on behalf of all purchasers of GlaxoSmithKline common stock and ADRs during the Class Period (the "Class"). The plaintiff is represented by Scott + Scott, LLC, which has a unique practice in prosecuting class actions combining diligence, integrity and client focus upon its cases.

Scott + Scott, LLC as a lead counsel recently settled the ImClone Securities Litigation for $75 million and the Mattel Securities Litigation for $122 million. Notably, it recently fought off three other plaintiffs' firms and the defendants' attorneys in the Halliburton Securities Litigation in which those attorneys attempted to settle the case for $6 million dollars. The Court removed the other three firms and their lead plaintiff clients and elevated Scott + Scott, LLC to Lead Counsel and its client to Lead Plaintiff in its own right. The firm was recently appointed to lead counsel positions in such cases as the Netflix Securities Litigation, Commerce Bancorp of New Jersey Securities Litigation and the Royal Dutch/Shell Pension Benefits Litigation. It has also been appointed to lead positions against such companies as Sprint, Emulex, ANR Re, priceline.com and many more.

Scott + Scott, a Connecticut-based law firm with offices in Chagrin Falls, Ohio and San Diego, California, is a law firm with a national practice and reputation. The firm is currently litigating major securities, antitrust and employee retirement plan cases throughout the United States and represents pension funds, charities, foundations, individuals and other entities worldwide -- in both class and non-class cases. Scott + Scott dedicates itself to client communication and satisfaction. Please visit our website at http://www.scott-scott.com (under reconstruction) to learn more about the firm, its practice and other cases. If you wish to discuss this action with an attorney or have any questions concerning this notice, your rights or any matter within our expertise, please contact attorney Neil Rothstein at nrothstein@scott-scott.com, Amy K. Saba at asaba@scott-scott.com, or Managing Partner David R. Scott at drscott@scott-scott.com or by calling 800-404-7770 (EST) by 12:00 p.m. or 800-332-2259 (PST) thereafter. You can dial direct in California at 619-233-4565.

Scott + Scott, LLC is based at 108 Norwich Avenue, Colchester, CT 06415; phone: 860/537-3818; fax: 860/537-4432. This release is issued in accordance with the applicable U.S. federal law.

More information on this and other class actions can be found on the Class Action Newsline at www.primezone.com/ca.

CONTACT:  Scott + Scott, LLC
          Neil Rothstein 
          619-233-4565